Women’s Heart Health: Understanding the Differences and Taking Action
Heart disease is the leading cause of death for women in the U.S., yet many women don’t realize how differently it can appear or progress in us. As caregivers, we…
In our ever-challenging industry, hospitals across the country have begun to enhance their capabilities in the cath lab by augmenting like-volume procedures. Typically, cardiac procedures such as diagnostic catheterizations and coronary intervention (i.e., PCI) have ruled lab utilization, but due to declining inpatient volume trends, technology advances, and focus on more complex procedures such as structural heart, Corazon has seen stagnant volume. In order to stay productive, cath labs should look beyond PCI into the untapped market of peripheral vascular.
The Clinical Case
Peripheral vascular, specifically peripheral artery disease (PAD) is a natural progression as the similarities to coronary artery disease (CAD) are strikingly similar. In fact, the correlation is so strong that the proportion of vascular patients with coronary artery disease and/or cardiovascular disease = 63%! Other extraordinary facts include:
The Business Case
Peripheral vascular has been, and continues to be, an untapped and under-diagnosed market. Even as long as 20 years ago, Corazon referred to vascular as “the diamond in the rough” due to the great volume and revenue potential that exists, again without much capital investment in the instance of a well-equipped lab.
Have you identified the opportunity in your hospital? If so, what has been your experience with ramping-up to the potential that exists? If not, what can Corazon do to help identify the opportunity in your market?
Additional Resources:
Sources: